Physician profile
Nathan S Sumner
NPI 1265652846
$651.26
in general payments reported to CMS, 2019-2025
16 companies · $25.39 in 2025
The $25.39 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $83.40 · 2021: $66.13 · 2022: $193 · 2023: $36.02 · 2025: $25.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $61.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $61.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $192.47 | 2019-2025 | |
| Allergan, INC. | $72.03 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $55.47 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $44.28 | 2019 | |
| Amgen INC. | $43.73 | 2019-2022 | |
| Corcept Therapeutics | $39.50 | 2020-2021 | |
| Acorda Therapeutics, INC | $38.76 | 2019 | |
| Aurinia Pharma U.S., INC. | $22.01 | 2022 | |
| Endo Pharmaceuticals INC. | $21.98 | 2022 | |
| Merck Sharp & Dohme LLC | $21.51 | 2019 | |
| Leo Pharma INC. | $20.97 | 2023 | Adbry |
| Biohaven Pharmaceutical Holding Company LTD. | $19.62 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.39 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.05 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.09 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dusa Pharmaceuticals, INC. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Sumner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.